DAWNZERA (donidalorsen) Becomes First FDA-Approved RNA-Targeted Prophylactic for Hereditary…
Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema…
Read More...
Read More...
